In research, Istituto Oncologico Romagnolo stands highest in Health Sciences (#9,184 of 16,688 worldwide) and Medicine (#8,067 of 14,558 worldwide), over all time.
Each strip is that field's whole ranked pool, with the notch where Istituto Oncologico Romagnolo sits in it, in the colour
of the band that rank falls in. The track under the rate is the rate itself: it carries no average mark, because the average
differs by field (from about 6% in Dentistry to 21% in Economics).
Which fields of science does Istituto Oncologico Romagnolo work in?
Life Sciences21%Physical Sciences11%Health Sciences51%Social Sciences17%
Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in 2022-now. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
more than its size predictsabout as predictedless
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 4.9×. Every wedge is a field page.
All 21 fields, with their numbers
Immunology and Microbiology4.88×1 works
Medicine2.59×14 works
Agricultural and Biological Sciences2.18×3 works
Psychology1.60×1 works
Business, Management and Accounting1.34×1 works
Chemical Engineering1.18×0 works
Arts and Humanities0.94×1 works
Earth and Planetary Sciences0.87×0 works
Economics, Econometrics and Finance0.81×0 works
Neuroscience0.79×0 works
Biochemistry, Genetics and Molecular Biology0.76×1 works
Pharmacology, Toxicology and Pharmaceutics0.70×0 works
What are the most cited papers from Istituto Oncologico Romagnolo?
The most cited paper from Istituto Oncologico Romagnolo is "Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study" (Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al., 2009), with 2,681 citations. Next come "CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group" (2,098) and "Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results" (1,209).
Which keywords describe research at Istituto Oncologico Romagnolo?
By fractional works in 2022-now, weighted toward what it does more of than the world: Prognostic Factors, Epidemiology, Rituximab, Immunotherapy, Lymphoma, Consumer Perception, Packaging Design and Chemotherapy.
▲ more of its work than of the world's◆ about the world's share▼ less than the world's
Size is fractional works in 2022-now in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 9 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 9 words, with their numbers
Epidemiology2▲ 2.3×28 topics
Prognostic Factors2▲ 13×7 topics
Immunotherapy1▲ 6.0×8 topics
Chemotherapy1▲ 5.6×9 topics
Quality of Life1▲ 2.8×9 topics
Rituximab1▲ 28×4 topics
Consumer Perception1▲ 16×1 topic
Lymphoma1▲ 24×3 topics
Packaging Design1▲ 366×1 topic
Which research topics does Istituto Oncologico Romagnolo publish most on?
Against the world's own shares: the tick on each track. Both are shares of its output, so they
sit on one scale and can be read against each other as well as against the world.
24%76%
openly available23.5%not open76.5%
World: 40% of research is openly available.
16%84%
with international co-authors16.3%domestic only83.7%
World: 18% is written across borders.
How has Istituto Oncologico Romagnolo's research output changed?
Output in 2022-2025 was 35% lower than in 2018-2021.
grewheldshrank
The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.
Its share of all research
Growing output can still be a shrinking share: all of science grows. This is Istituto Oncologico Romagnolo as a percentage of every work published that year, 0.000093% in 2024.
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.
Discussion
Ask a question or share a note about Istituto Oncologico Romagnolo. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.